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BDDrFVIII (Refacto AF) based on the difference in half-life reported, even if BDDrF-
VIII has a lower price per IU. [1] Recht et al. Hemophilia 2009:1–12; [2] EMA 
Assessment report Refacto AF. London March 2009. http://www.ema.europa.eu/
humandocs/PDFs/EPAR/Refacto/refactoaf-H-232-II-59-68-AR.pdf
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1ANOVA—Knowledge Translation, Rio de Janeiro, RJ, Brazil; 2Janssen-Cilag, São Paulo, SP, 
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OBJECTIVES: To conduct cost-effectiveness and budget impact analysis (BIA) of 
OROS hydromorphone versus CR morphine and CR oxycodone for moderate to 
severe cancer pain from the public payer perspective in Brazil. METHODS: A decision 
tree followed by a Markov Model with a 12 month time horizon was developed with 
data from the Phase III trial Hanna 2008. The achievement of mild pain (worst pain 
scores < 4) was considered as outcome. Only direct medical costs were considered and 
unit costs were obtained from Brazilian ofﬁ cial lists. For the BIA, 10% of currently 
used CR morphine daily doses was substituted for equivalent OROS hydromorphone 
doses. The same rational was adopted for CR oxycodone comparison. Univariate 
deterministic sensitivity analyses showed that the results remained consistent through 
model parameters variation. RESULTS: OROS hydromorphone showed 1.66 addi-
tional months in mild pain per patient per year when compared to both CR morphine 
and CR oxycodone. Annual treatment costs were 2.401 BRL, 1.256 BRL and 5.114 
BRL for OROS hydromorphone, CR morphine and CR oxycodone respectively. The 
incremental cost-effectiveness ratio was 689 BRL per additional month in mild pain 
per patient per year, when OROS hydromorphone was compared to CR morphine. 
Versus CR oxycodone, OROS hydromorphone was more effective with fewer costs, 
being cost saving (ICER -1,634 BRL). BIA results showed that the substitution of 10% 
of current utilization of CR morphine for OROS hydromorphone and CR oxycodone 
would result in a budgetary impact of 118,722 BRL and 347,295 BRL, respectively. 
CONCLUSIONS: OROS hydromorphone is cost saving when compared to CR oxy-
codone and is more cost-effective than CR oxycodone when both are compared to 
the current scenario of chronic cancer pain treatment with CR morphine, with a lower 
budgetary impact.
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FROM THE UK PAYER PERSPECTIVE
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OBJECTIVES: Golimumab is a novel TNF-α inhibitor for treatment of patients with 
severe active ankylosing spondylitis (AS). This study evaluated the cost-effectiveness 
of golimumab and its appropriate comparators in the treatment of AS from UK 
National Health Service perspective. METHODS: A Markov model with an initial 
decision tree was developed to simulate the progression of a hypothetical cohort of 
active AS patients for 20 years. The primary outcome measure was quality-adjusted 
life-years (QALYs) estimated using Bath Ankylosing Spondilytis Functional Index 
(BASFI) whereas the primary response measure was ≥50% improvement in Bath 
Ankylosing Spondilytis Disease Activity Index (BASDAI) at 12 weeks. Direct costs 
including medication costs and AS management costs were included. Golimumab was 
compared with conventional treatment and other TNF-α inhibitors. Costs and out-
comes were discounted at 3.5%. RESULTS: All TNF-α inhibitors were superior to 
conventional treatment and comparable to each other on BASDAI response. The 
incremental cost-effectiveness ratio (ICER) for golimumab was £15,353 per QALY 
compared to conventional treatment. The probability of golimumab being cost-effec-
tive at a threshold of £30,000/QALY was 92%. Compared to etanercept and adali-
mumab, golimumab generated marginally more QALYs at marginally more costs. 
CONCLUSIONS: Golimumab may be considered as a cost-effective treatment alterna-
tive for patients with AS. With comparable costs and efﬁ cacy to other TNF-α inhibi-
tors, golimumab’s position in the treatment pathway is likely to be driven by patient 
and physician choice.
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OBJECTIVES: The Dutch reimbursement policy for expensive inpatient medicines 
requires outcomes research after four years of temporary reimbursement. Based on a 
retrospective study, we explored the cost-effectiveness of bortezomib for relapsed/
refractory multiple myeloma in Dutch daily practice. METHODS: Detailed clinical 
data from a real-world cohort of 72 patients treated with bortezomib and 67 patients 
never treated with bortezomib were collected from medical records. Validity of the 
incremental cost-effectiveness was assessed by comparing baseline prognosis between 
bortezomib and non-bortezomib patients. Clinical effectiveness was evaluated by 
comparing Kaplan-Meier survival estimates. Costs of resource use from a hospital 
perspective were based on patient-level data. RESULTS: Prognostic factors for bort-
ezomib patients were signiﬁ cantly different compared to non-bortezomib patients. 
Incremental analyses for bortezomib versus non-bortezomib patients were therefore 
not performed. Total mean costs and median survival from start of relapsed/refractory 
treatment for bortezomib patients were c84,042 and 33.2 months. Bortezomib 
accounted for 21% of total costs among these patients. For non-bortezomib patients, 
total mean costs and median survival from start of relapsed/refractory treatment were 
c54,435 and 21.6 months. The proportion of patients still in follow-up at the end of 
data collection was slightly higher in bortezomib versus non-bortezomib patients 
(51% vs. 46%). Total mean costs for bortezomib patients did not differ signiﬁ cantly 
when excluding patients still in follow-up. For non-bortezomib patients, total mean 
costs differed signiﬁ cantly when excluding patients still in follow-up, mainly due to 
high costs of lenalidomide treatment, stem cell transplants and inpatient hospital stays. 
CONCLUSIONS: Our real-world data challenged the assessment of the incremental 
cost-effectiveness of bortezomib versus other treatments in the indication of relapsed/
refractory multiple myeloma. It was possible to estimate the cost and effects for 
bortezomib patients in daily practice to determine the real-world value. Data synthesis 
incorporating effectiveness for the relevant comparator might facilitate estimation of 
a valid ICER.
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OBJECTIVES: Estimate the cost-effectiveness of Pregabalin (PGB) versus Usual Care 
(UC) in refractory out-patients with Neuropathic Pain (NeP) treated according to 
usual medical practice in Primary Care settings (PCS) in Spain. METHODS: Data 
extracted from a 12-week non-interventional prospective study conducted to ascertain 
the cost of NeP were used. PGB naïve patients treated with UC or PGB, matched by 
age (+5 years), sex and pain intensity (+5 pts), refractory (≥40VAS-McGill) to previous 
treatment during the prior 6 months, were selected in a 1:1 ratio. Patients could switch 
to PGB (monotherapy/add-on) or to UC (non-narcotics, opiates, antidepressants and/
or anticonvulsants). Time horizon was 12 weeks. Effectiveness was quality-adjusted 
life-years (QALY) gain. Perspectives of the National Health Service (NHS) and society 
(2006) were included, and expressed as an incremental cost-effectiveness ratio (ICER). 
Bootstrapping techniques (10,000 re-samples) were used to obtain the probabilistic 
ICER, its 95% percentile conﬁ dence interval (CI) and the cost-effectiveness accept-
ability curve. RESULTS: A total of 160 patient-pairs were extracted. Compared with 
UC, PGB was associated with signiﬁ cantly higher QALY gain; 0.0374 ± 0.0367 vs. 
0.0224 ± 0.0313 (P < 0.001). Notably, although drug costs were higher for PGB (c251 
± 125 vs. c104 ± 121, P < 0.001), its QALY gain did not incur a higher overall total 
cost (c1335 ± 1302 vs. c1387 ± 1489; P = 0.587), nor higher health care costs (c529 
± 438 vs. c560 ± 672; p = 0.628). In fact, the ICER was dominant for total and health 
care costs, with CIs respectively, dominant-c17,268, and dominant-c6,508. ICER for 
drug costs was c10,672/QALY (dominant-c19,858). The 99% of the re-samples were 
below the threshold of c30,000/QALY. CONCLUSIONS: Versus usual care in the 
community medical setting, pregabalin is highly cost-effective in the treatment of 
refractory NeP patients. The high indirect costs and increased health care costs associ-
ated with the treatment of refractory patients, which offset higher cost of pregabalin, 
highlight the economic burden of the condition on society.
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OBJECTIVES: To evaluate cost-effectiveness of biologics used in patients with psoria-
sis in Colombia and Peru. METHODS: We estimated direct costs of etanercept, 
adalimumab, ustekinumab and inﬂ iximab based on their labels for ﬁ rst/induction year 
and second/maintenance year (EUR1 = COL$2340 = SOL$357). For etanercept we 
considered two induction schemes: 50 mg weekly 52 weeks-D1- and 100 mg 12 weeks 
followed by 50 mg 40 weeks-D2-. Effectiveness was evaluated as 75% reduction in 
Psoriasis Area and Severity Index-PASI 75- from meta-analysis presented by Hawkins 
et al. in the 14th International ISPOR: inﬂ iximab = 80%; ustekinumab = 69%; adali-
mumab = 59%; etanerceptD2- = 52%; etanerceptD1 = 39%. Inﬂ iximab and 
ustekinumab effectiveness were not signiﬁ cantly different. However, both were signiﬁ -
cantly superior to etanercept (D1 and D2). RESULTS: In Colombia, Ustekinumab was 
dominant (c29.012 in 2 years) generating cost savings of −c4.416 vs. etanerceptD1; 
−c7.411 vs. adalimumab; −c8.119 vs. etanerceptD2 and −c25,340 vs. inﬂ iximab; with 
higher or same effectiveness than the other biologics used in that country. In Peru, all 
the options were more effective and more costly than the standard of care (etaner-
ceptD1). The ICER per patient with PASI 75 of etanerceptD2, adalimumab, 
ustekinumab and inﬂ iximab, compared to etanerceptD1 were c21.654; c19,860, 
c13,036 and c29,008, respectively. Then, the efﬁ ciency frontier was formed by etan-
erceptD1, ustekinumab and inﬂ iximab. Given evidence shows the last two products 
do not have effectiveness signiﬁ cant differences, ustekinumab became the dominant 
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option. An additional analysis was done supposing that inﬂ iximab’s effectiveness was 
superior to ustekinumab’s. The ICER per patient with PASI 75 between these products 
was c220,352 in Colombia and c50,989 in Peru. These values were higher than 
Colombian and Peruvian health systems’ willingness to pay per PASI 75 (c40.334 and 
c29,242, respectively), calculated based on average effectiveness and costs of biologics. 
CONCLUSIONS: In the studied LA countries, Ustekinumab resulted the most cost-
effective biologic, even being cost-saving in Colombia. These results corroborate those 
observed in European countries.
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OBJECTIVES: To compare treatment costs and cost-effectiveness results for biologics 
approved for the treatment of moderate to severe psoriasis from the perspective of a 
public payer in Brazil. METHODS: Annual treatment costs were calculated based on 
the number of vials used, as deﬁ ned in the label for each biologic, and from the price 
per vial. The prices of etanercept, adalimumab and inﬂ iximab were obtained from 
purchase disclosures by the Brazilian Ministry of Health. As ustekinumab, the latest 
biologic approved for psoriasis, has not yet been purchased by that Ministry, its list 
price after deducting the mandatory discount for government sales (22.85%) was 
considered. The effectiveness of each treatment was deﬁ ned by a recent metanalysis 
as the PASI75 response at the primary endpoint for each drug. The average patient 
weight was assumed at 70 kg. RESULTS: Ustekinumab has the lowest treatment cost 
across the biologics in both induction and maintenance years with the least number 
of vials used. With a total of 4 applications during a maintenance year, ustekinumab 
has the lowest treatment cost, followed by inﬂ iximab (55% more expensive), adalim-
umab (62% more expensive) and etanercept (75% more expensive). Combining the 
cost and effectiveness results, ustekinumab has the lowest cost per response, followed 
by inﬂ iximab (44% less cost-effective), adalimumab (104% lesss cost-effective) and 
etanercept (152% less cost-effective). CONCLUSIONS: With the lowest treatment 
cost, ustekinumab is an important treatment option in moderate to severe psoriasis. 
When comparing the cost-per-response across biologics, ustekinumab is further dif-
ferentiated from the remaining biologics. Ustekinumab represents a rare situation in 
Brazil combining the lowest treatment cost and a high effectiveness result.
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TREATMENT OF PATIENTS WITH ADVANCED FOLLICULAR 
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OBJECTIVES: Evaluate costs and beneﬁ ts of rituximab in combination with cyclophos-
phamide/vincristine/prednisolone chemotherapy regimen (R-CVP) versus CVP alone in 
previously untreated patients with indolent non-Hodgkin lymphoma (NHL). 
METHODS: Cost-effectiveness (Life-years Gained—LYG) and cost-utility analysis 
(Quality Adjusted Life-years—QALYs) were performed for a time horizon of 10 years 
according to a Markov economic model with three health states (“progression free 
survival”, “progression” and “death”) and monthly cycles. Data from a phase III clinical 
trial (Marcus R. et al 2007) was used and expanded in the model to include unpublished 
53-month median follow-up data. Survival after ﬁ rst-line therapy was estimated from 
the Scotland and Newcastle Lymphoma Group registry data and utilities were derived 
from a UK study. Resource consumption was estimated by a Portuguese expert panel. 
Costs were calculated from the Portuguese Health System perspective through ofﬁ cial 
data with prices updated to 2010. Only direct medical costs were considered. Costs and 
consequences were discounted at 5% per annum. Deterministic and probabilistic sensi-
tivity analyses were performed around assumptions on the time horizon, costs, utilities 
and excess mortality rate due to progression applied in the base-case analysis. RESULTS: 
The 10-year base-case analysis showed a lower total cost per patient with CVP alone 
(c88,373) versus R-CVP (c89,899). Life expectancy and quality-adjusted life expectancy 
per patient were higher with R-CVP (6.361 and 4.166, respectively) versus CVP alone 
(5.557 and 3.438, respectively), representing increases of 0.804 in LYG and 0.728 in 
QALYs gained. The incremental cost per QALY gained was c2097 (base-case) and 
c6006 considering a lifetime horizon (25 years). The sensitivity analyses conﬁ rmed the 
robustness of the model. CONCLUSIONS: This study demonstrates that the combina-
tion R-CVP in previously untreated NHL patients improves life expectancy and is a 
cost-effective alternative to CVP in Portugal.
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OBJECTIVES: To assess the cost-effectiveness of using a lidocaine 5% medicated 
plaster in the treatment of post-herpetic neuralgia (PHN) compared with gabapentin 
and pregabalin from the perspective of the payer in Spain. METHODS: A Markov 
model was constructed to calculate the cost-effectiveness of gabapentin, pregabalin 
and lidocaine plaster in terms of the cost per quality-adjusted life-year (QALY) gained 
when used over a six-month time horizon in patients with PHN. The model structure 
allowed for differences in costs, utilities and transition probabilities between the initial 
30-day run-in period and maintenance therapy. Transition probabilities were based 
on the comparative and long-term clinical trials identiﬁ ed through a systematic litera-
ture review. Missing data, including resource utilization, were obtained from a Delphi 
panel, and cost data were obtained from the ofﬁ cial price/tariffs lists. Utilities were 
derived from the literature and were supplemented and validated by the Delphi panel. 
RESULTS: The total cost of treatment with the lidocaine plaster was c1414 per patient 
at a daily consumption of 1.1 plasters, compared with c1100 for gabapentin (average 
dosage 2100 mg/day during maintenance phase), and c1348 for pregabalin (average 
dosage 488 mg during maintenance phase). Lidocaine plaster generated 0.428 QALYs, 
compared with 0.339 for gabapentin, and 0.399 for pregabalin. Lidocaine plaster 
therefore had an incremental cost-effectiveness ratio of c3525/QALY gained relative 
to gabapentin at generic price, and c742/QALY relative to pregabalin. Scenario analy-
ses and extensive one-way sensitivity analyses on all parameters including the time 
horizon conﬁ rmed the robustness of the results. CONCLUSIONS: The lidocaine 5% 
plaster is a highly cost-effective treatment for PHN in Spain.
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OBJECTIVES: Patients refractory to older therapies for neuropathic pain (NeP) have few 
remaining therapeutic options. To demonstrate pregabalin’s value to decision-makers, this 
study evaluates the cost-utility of pregabalin in the treatment of patients with refractory 
neuropathic pain in Sweden, from a health care and societal perspective. METHODS: A 
discrete event simulation (DES) model was constructed to compare pregabalin with usual 
care. Pain proﬁ les were generated for the pregabalin and usual care cohorts using clinical 
data from a synthesis of ﬁ ve non-randomised pregabalin studies in treatment-refractory 
patients. Utility data were generated from a UK survey of patients with NeP, which were 
used in a recent successful Health Technology Assessment (HTA) of pregabalin in the UK 
[1]. Cost data were generated from the Swedish TLV’s product price database, a national 
NeP register, and a regional register study. Indirect costs were estimated from published 
sources. One-way, and probabilistic sensitivity analyses (PSA), evaluated uncertainty in 
the model’s output. RESULTS: The incremental cost-effectiveness ratio (ICER) for prega-
balin compared to usual care was 51,616 SEK/c5,364 (123,993 SEK/c12,886 excluding 
indirect costs). One-way sensitivity analyses conﬁ rmed the clinical input data as the main 
driver of the model; even considerable changes to all other input parameters had only a 
modest effect on the ICER. The PSA generated an ICER of 41,634 SEK/c4,327 (with 
indirect costs included), suggesting that the model is relatively insensitive to the combined 
variation in all input parameters; this is evident in the ICER scatter, in which the cost-
effectiveness pairs are tightly grouped. CONCLUSIONS: Our study found pregabalin to 
be highly cost-effective compared to usual care in Swedish treatment-refractory patients. 
Moreover, the PSA showed pregabalin’s favourable cost-effectiveness to be robust in all 
modelled scenarios, with an ICER well below a conservative threshold of 347,495 SEK /
c36,113/£30,000. [1] Scottish Medicines Consortium (SMC). Pregabalin re-submission, 
advice issued May 2009.
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OBJECTIVES: Patients with moderate to severe forms of psoriasis reveal lower quality 
of life. This QoL deterioration comes together with their productivity loss and dis-
ability. Therefore, we calculated indirect costs, from societal perspective, of psoriasis 
in Czech Republic. METHODS: This calculation was based on 6 months-retrospective 
self-reported questionnaire. We included 179 patients with psoriasis, aged 18–62 years 
either at working status, partly-disabled or fully-disabled. For calculation of indirect 
costs we included costs associated with absenteeism (number of missed workdays) and 
costs associated with disability pension. We used friction costs approach (FCA) with 
deﬁ ned friction period of 6 months (130 workdays). The height of average monthly 
income in year 2009, c851.3 and height of average monthly partly-disability pension 
and fully-disability pension c229.44 and c365.61, respectively were used for calcula-
tion. Indirect costs were expressed as mean value per one patient with moderate to 
severe form of psoriasis per one year—2009. Clinical data (PASI score, BSA index and 
QoL) were collected by dermatologists. RESULTS: Average patients’ age was 45.34 
years (23–62 years), average time from diagnosis was 23.9 years. Mean BSA index 
and PASI score were 26.78% and 13.32, respectively. Occurrence of psoriatic arthritis 
was 34.1%. Percentage of fully-disabled and partly-disabled patients was 9.5 and 
6.1%, respectively. 18.4% of patients reported incapacity to work with average dura-
tion of 28.8 workdays in previous 6 months. Mean costs associated with absenteeism, 
partly-disability pension and fully-disability pension were c214, c168 and c414, 
respectively. CONCLUSIONS: By using friction cost approach total mean indirect 
costs of patients with moderate to severe forms of psoriasis were c796 per patient per 
year. The height of indirect costs was correlated with PASI score, BSA index and QoL.
